

## Table of Contents

Volume 104, Issue 5: May 2019

### Cover Figure

---

Peripheral blood smear from a patient with primary myelofibrosis showing thrombocytosis with platelet anisocytosis and marked morphological alterations. Courtesy of Prof. Rosangela Invernizzi.

### Editorials

---

- 857** Factor H: a novel modulator in sickle cell disease  
*Wassim El Nemer and Bérengère Koehl*
- 859** A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes  
*Mahasweta Gooptu and John Koreth*
- 862** Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?  
*Giuseppe Saglio et al.*
- 864** Mogamulizumab *versus* investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all for one or none for all?  
*William Johnson et al.*

### Perspective Article

---

- 868** Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia  
*Ross L. Levine and Peter J.M. Valk*

### Review Articles

---

- 872** Evolutionary trajectory of leukemic clones and its clinical implications  
*Amos Tuval and Liran I Shlush*
- 881** CRISPR to fix bad blood: a new tool in basic and clinical hematology  
*Elisa González-Romero et al.*

### Articles

---

#### *Hematopoiesis*

- 894** Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow  
*Zhijie Wu et al.*

#### *Red Cell Biology & its Disorders*

- 907** Finely-tuned regulation of AMP-activated protein kinase is crucial for human adult erythropoiesis  
*Meriem Ladli et al.*
- 919** Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule  
*Elisabetta Lombardi et al.*

#### *Myelodysplastic Syndromes*

- 929** Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation  
*Nico Gagelmann et al.*

#### *Myeloproliferative Neoplasms*

- 937** Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms  
*Alicia Arenas Cortés et al.*
- 947** EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis  
*Alessandro M. Vannucchi et al.*

#### *Chronic Myeloid Leukemia*

- 955** Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV  
*Christian Michel et al.*

*Acute Myeloid Leukemia*

- 963** The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase  $\gamma$ , impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia  
*Dana Yehudai et al.*
- 973** The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells  
*Isabella Spinello et al.*
- 986** Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG  
*Michael J. Burke et al.*

*Non-Hodgkin Lymphoma*

- 993** Mogamulizumab *versus* investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma  
*Adrienne A. Phillips et al.*

*Chronic Lymphocytic Leukemia*

- 1004** The involvement of microRNA in the pathogenesis of Richter syndrome  
*Katrien Van Roosbroeck et al.*
- 1016** Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies  
*Aoula Al-Zabeeby et al.*

*Plasma Cell Disorders*

- 1026** Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis  
*Hedwig M. Blommestein et al.*

*Platelet Biology & its Disorders*

- 1036** Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia  
*Tadbir K. Bariana et al.*

*Coagulation & its Disorders*

- 1036** Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A  
*Sandrine Delignat et al.*

*Stem Cell Transplantation*

- 1055** HLA discrepancy between graft and host rather than between that graft and first donor impact the second transplant outcome  
*Yoshinobu Maeda et al.*

*Cell Therapy & Immunotherapy*

- 1062** Human stem cells transplanted into the rat stroke brain migrate to the spleen via lymphatic and inflammation pathways  
*Kaya Xu et al.*
- 1074** Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the major human platelet autoantigen glycoprotein IIb/IIIa in HLA-transgenic mice  
*Lindsay S. Hall et al.*

*Quality of life*

- 1084** Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors  
*Navneet S. Majhail et al.*

**Letters to the Editor**

Letters are available online only at [www.haematologica.org/content/104/5.toc](http://www.haematologica.org/content/104/5.toc)

- e179** A novel gain-of-function mutation of Piezo1 is functionally affirmed in red blood cells by high-throughput patch clamp  
*Maria G. Rotordam et al.*  
<http://www.haematologica.org/content/104/5/e179>
- e184** The population dynamics of hemoglobins A, A<sub>2</sub>, F and S in the context of the hemoglobinopathies HbS and  $\alpha$ -thalassemia in Kenyan infants  
*Alex W. Macharia et al.*  
<http://www.haematologica.org/content/104/5/e184>
- e187** Detection and characterization of homozygosity of mutated *CALR* by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high *CALR* mutation loads or with progressive disease  
*Anna Stengel et al.*

- e191** <http://www.haematologica.org/content/104/5/e187>  
Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein  
*Haruka Shinohara et al.*  
<http://www.haematologica.org/content/104/5/e191>
- e195** Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions  
*Lijun Wen et al.*  
<http://www.haematologica.org/content/104/5/e195>
- e200** Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias  
*Zhen-Tang Lao et al.*  
<http://www.haematologica.org/content/104/5/e200>
- e204** T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development  
*Charles E. de Bock et al.*  
<http://www.haematologica.org/content/104/5/e204>
- e208** Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort  
*Maria Winqvist et al.*  
<http://www.haematologica.org/content/104/5/e208>
- e211** Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis  
*Simon Rule et al.*  
<http://www.haematologica.org/content/104/5/e211>
- e215** A prospective description of HIV-associated multicentric Castleman disease in Malawi  
*Tamiwe Tomoka et al.*  
<http://www.haematologica.org/content/104/5/e215>

## Case Reports

Case Reports are available online only at [www.haematologica.org/content/104/5.toc](http://www.haematologica.org/content/104/5.toc)

- e218** Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib  
*Dylan Graetz et al.*  
<http://www.haematologica.org/content/104/5/e218>
- e222** Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.  
*Gianluigi Reda et al.*  
<http://www.haematologica.org/content/104/5/e222>
- e224** Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia  
*Othman Al-Sawaf et al.*  
<http://www.haematologica.org/content/104/5/e224>

## Comments

Comments are available online only at [www.haematologica.org/content/104/5.toc](http://www.haematologica.org/content/104/5.toc)

- e227** Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations  
*Murali Janakiram et al.*  
<http://www.haematologica.org/content/104/5/e227>
- e228** Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations"  
*Adrienne A. Phillips*  
<http://www.haematologica.org/content/104/5/e227>

## Retraction

- e229** GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells  
*Beibei Zhang et al.*  
<http://www.haematologica.org/content/104/5/e229>